{"disease":{"id":"met-exon-14-mutation","name":"met exon 14 mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06161051","title":"Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04270591","title":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":183,"lead_sponsor_name":"Haihe Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT06908993","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":133,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT04647838","title":"Tepotinib in Solid Tumors Harboring MET Alterations","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Chungbuk National University Hospital","has_results":false},{"nct_id":"NCT06054191","title":"Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07122882","title":"Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT07153770","title":"Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05800340","title":"Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}